In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

Q: Objective: The aim of this study was to further clarify clinical characteristics and predict mortality risk among patients with viral pneumonia. Methods: A total of 528 patients with viral pneumonia at RuiJin hospital in Shanghai from May 2015 to May 2019 were recruited. Multiplex real-time RT-PCR was used to detect respiratory viruses. Demographic information, comorbidities, routine laboratory examinations, immunological indexes, etiological detections, radiological images and treatment were collected on admission. Results: 76 (14.4%) patients died within 90 days in hospital. A predictive MuLBSTA score was calculated on the basis of a multivariate logistic regression model in order to predict mortality with a weighted score that included multilobular infiltrates (OR = 5.20, 95% CI 1.41-12.52, p = 0.010; 5 points), lymphocyte 0.8 * 10 9 /L (OR = 4.53, 95% CI 2.55-8.05, p < 0.001; 4 points), bacterial coinfection (OR = 3.71, 95% CI 2.11-6.51, p < 0.001; 4 points), acute-smoker (OR = 3.19, 95% CI 1.34-6.26, p = 0.001; 3 points), quit-smoker (OR = 2.18, 95% CI 0.99-4.82, p = 0.054; 2 points), hypertension (OR = 2.39, 95% CI 1.55-4.26, p = 0.003; 2 points) and age 60 years (OR = 2.14, 95% CI 1.04-4.39, p = 0.038; 2 points). 12 points was used as a cut-off value for mortality risk stratification. This model showed sensitivity of 0.776, specificity of 0.778 and a better predictive ability than CURB-65 (AUROC = 0.773 vs. 0.717, p < 0.001). Conclusion: Here, we designed an easy-to-use clinically predictive tool for assessing 90-day mortality risk of viral pneumonia. It can accurately stratify hospitalized patients with viral pneumonia into relevant risk categories and could provide guidance to make further clinical decisions.

A: Citation: Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score
****
Q: The presence of immunoglobulin oligoclonal bands in the cerebrospinal fluid of Multiple Sclerosis (MS) patients supports the hypothesis of an infectious etiology, although the antigenic targets remain elusive. Neurotropic mouse hepatitis virus (MHV) infection in mice provides a useful tool for studying mechanisms of demyelination in a virus-induced experimental model of MS. This study uses Affymetrix microarray analysis to compare differential spinal cord mRNA levels between mice infected with demyelinating and non-demyelinating strains of MHV to identify host immune genes expressed in this demyelinating disease model. The study reveals that during the acute stage of infection, both strains induce inflammatory innate immune response genes, whereas upregulation of several immunoglobulin genes during chronic stage infection is unique to infection with the demyelinating strain. Results suggest that the demyelinating strain induced an innate-immune response during acute infection that may promote switching of Ig isotype genes during chronic infection, potentially playing a role in antibody-mediated progressive demyelination even after viral clearance.

A: Demyelinating strain of mouse hepatitis virus infection bridging innate and adaptive immune response in the induction of demyelination
****
Q: These authors contributed equally to this work White powder, yield 49%, m. p. >300 o C; 1 H-NMR (DMSO-D 6 ) H 6.95 (1H, br, s, H10), 7.49-7.95 (5H, m. H15-H16), 8.58 (2H, s, H2 and H11), 12.41 (1H, s, H1); 13 C-NMR (DMSO-d 6 ) 121.9 (C15 ). QTOF-MS m/z calcd for C 12 H 9 KN 5 OS M+K + 310.39 found 310.33. 7 General procedure for the N-alkylation of acetamide-thioguanine The synthesis of 17 and 20 followed the general procedure for N-alkylation Salvatore et al., 2002 4 . Briefly, 138.23 mg of 4 A Molecular Sieves (MS) was suspended into 3 mL of DMF. Cessium hydroxide monohydrate (CsOH.H 2 O) (140 L) was added into the mixture and then stirred up for 10 minutes at the room temperature. The stirring was continued while adding N-(6-mercapto-9H-purin-2-yl)acetamide (MH022; 0.5 mmol) into the mixture for 30 minutes at the same temperature. Lastly, cyclopentyl bromide (0.6 mmol) was added into the mixture and the stirring was continued while monitoring the reaction's progress using TLC with CHCl 3 : acetone (3:1) as a solvent. After the reaction completed, the mixture was diluted with 70 mL of water and then extracted using 3 x 70 mL of EtO-Ac. The organic phase was collected, washed with 3 x 70 mL of water and then dried over anhydrous magnesium sulfate. This organic phase was then evaporated in vacuo and purified using PLC to afford the product as a white off powder. (15) White powder; yield 86%; m.p 154-156 o C; max / cm -1 (KBr) 3211 (NH), 1585 (C=O); 1 H-NMR (DMSO-D 6 ) H 1.73 (4H, m, H12 and H13), 2.19 (3H, s,H19), 2.26 (4H, m, H11 and H14), 2.65 (1H. m, H10), 8.03 (1H, s, H2), 12.85 (1H, br, s, H16); C 24.0 (MS m/z calcd for C 12 H 16 N 5 OS M+H + 278.35 found 278.13. White powder, yield 64%, m. p. >300 o C; 1 H-NMR (DMSO-D 6 ) H 1.09 (3H, t, H17), 1.19 (3H, t, H19), 2.55 (2H, q, H18), 3.29 (2H, q, H16), 8.61 (1H, s, H2), 11.97 (1H, br, s, H1); 13 C-NMR (DMSO-d 6 ) 8.

A:
Supporting Information Thioguanine-based DENV-2 NS2B/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling
****